Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Pipeline

Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine

 April 21, 2026

BioPharma Dive

The startup is developing modified DNA therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.

PipelineGene Therapy PlatformRead full story

Post navigation

FDA kicks off review of Roche’s Gazyva for wider lupus use →
← The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com